ClinicalTrials.gg
TerminatedNCT06085118OLAFUpdated Nov 16, 2026

Observatory on Cow's Milk Protein Allergy

An observational study in Food Allergy, sponsored by Nutricia Nutrition Clinique. Terminated at 2 sites in France. Open to participants aged Up to 8 Months. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Nutricia Nutrition Clinique (part of Danone) · Observational

Why this study was terminated
difficulties in recruiting investigating physicians and patients, both of which are linked to the duration of recruitment (3 years), patient follow-up (5 years), the indispensable involvement of parents in filling in numerous questionnaires on a regu
Updated Nov 16, 2026Now TerminatedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
21
Ages
Up to 8 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Food Hypersensitivity with a site in France — 4 open to participants now, 6 under way, 2 of them phase 3. Food Hypersensitivity · France.

Enrollment
13th of 13
21 · median 100
Started
2024
with 1 other
Observational
13 of 31
2 open now
Registered
25th of 31
by date

Among the 31 studies in Food Hypersensitivity with a site in France, this one is the 13th largest by enrollment of the 13 observational ones that give a count, is one of 2 that started in 2024, is one of 13 observational ones, and was the 25th registered.

Food Hypersensitivity

378 studies on the registry are indexed under Food Hypersensitivity; 90 are open to participants now.

Browse Food Hypersensitivity studies →

Open to participants now

4 of the 31 studies in Food Hypersensitivity with a site in France are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 52 Food Hypersensitivity studies recruiting now, 8 (15%) set no upper age limit and 40 (77%) stop at 75 or younger; 44 take children under 18; 17 take healthy volunteers.

This study: Up to 8 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Food Hypersensitivity with a site in France, or all of them as a file.
02

Study summary

The purpose of this study is to describe the symptoms and their evolution up to the age of 5 years in a population of newly diagnosed infants with a suspected or confirmed allergy to cow proteins, for whom the doctor prescribed the Pepticate® Syneo® replacement formula as soon as they were diagnosed.

The Pepticate® Syneo® product is an advanced protein hydrolyzate, food type intended for special medical purposes. This is a product already available on the market.

Read the detailed description

This is a prospective, observational, descriptive, longitudinal, multicentric study aimed at describing a cohort of infants with a recently suspected or confirmed allergy to cow's milk protein, who were treated in outpatient and inpatient settings.

The recruitment of patients eligible for this observatory will be done via community medicine (private practices of pediatricians and general practitioners) as well as in hospitals throughout France.

03

Conditions studied

  • Food Allergy

Browse trials for

04

Who can participate

Ages eligible
Up to 8 Months
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The target population of our project will be infants up to and including 8 months of age (up to 8 months and 29 days), treated for a suspected or confirmed, newly diagnosed cow protein allergy requiring, according to the investigator's judgement, an initial prescription of the Pepticate® Syneo® advanced cow protein hydrolysate infant formula.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants up to and including 8 months (up to 8 months and 29 days).
  • Initial diagnosis of allergy to cow proteins, suspected (clinical presumption) or confirmed.
  • Prescription of the substitution formula Pepticate® Syneo, according to the doctor's judgement, whether the child is under mixed or weaned breastfeeding.
  • Authorisation from a legal representative for the child to take part in the observatory and to collect personal information about the child and the family.
  • Membership of the social security system.

Exclusion criteria

Exclusion Criteria:

  • Infants who have already received partial or total replacement infant formula (regardless of the type of infant formula).
  • to the use of symbiotics (short small intestine, parenteral nutrition, post-pyloric feeding, central venous catheter) due to the use of Pepticate® Syneo®.
  • Diagnosis of severe cow protein allergy requiring an infant amino acid formula from the outset.
  • The child's legal guardian is protected (under legal protection, or deprived of liberty by judicial or administrative decision).
  • The legal representative is unable to understand the study protocol.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
21 participants (actual)
Patient registry
No

Groups and cohorts

  • Patient

    Infants up to and including 8 months of age (up to 8 months and 29 days), treated for a suspected or confirmed cow protein allergy.

    Other: Pepticate® Syneo®

Interventions

  • OtherPepticate® Syneo®

    Introduction of the nutritional treatment Pepticate® Syneo® (high protein hydrolysate), as a foodstuff for special medical purposes (product already available on the market).

06

What researchers measure

Primary outcomes

  1. Number and proportion of symptoms

    Numbers and proportion of symptoms (cutaneous, gastrointestinal, respiratory...), and their evolution according to the different forms of cow protein allergy: immediate Immunoglobulin E mediated, delayed non-Immunoglobulin E mediated or mixed and acute food protein-induced enterocolitis syndrome.

    Time frame: 5 years

07

Study locations

2 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2024 to primary completion in Sep 2024, 0 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: start Jun 2024 → Sep 2024, primary completion Nov 2031 → Sep 2024 and completion Nov 2031 → Sep 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2023
First posted
Oct 16, 2023
StartActual
Sep 22, 2024was Jun 2024
Primary completionActual
Sep 22, 2024was Nov 2031
CompletionActual
Sep 22, 2024was Nov 2031
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated difficulties in recruiting investigating physicians and patients, both of which are linked to the duration of recruitment (3 years), patient follow-up (5 years), the indispensable involvement of parents in filling in numerous questionnaires on a regu
changed Nov 16, 2026
Start date
Jun 17, 2024→Sep 22, 2024
Nov 16, 2026
Primary completion
Nov 2031→Sep 22, 2024 (actual)
Nov 16, 2026
Study completion
Nov 2031→Sep 22, 2024 (actual)
Nov 16, 2026
Enrollment
3000 (estimated)→21 (actual)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Recruiting→Terminated
    Why stopped difficulties in recruiting investigating physicians and patients, both of which are linked to the duration of recruitment (3 years), patient follow-up (5 years), the indispensable involvement of parents in filling in numerous questionnaires on a regu
    Start date Jun 17, 2024→Sep 22, 2024
    Primary completion Nov 2031→Sep 22, 2024 (now actual)
    Study completion Nov 2031→Sep 22, 2024 (now actual)
    Enrollment 3000 (estimated)→21 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06085118
Responsible party
Sponsor
First posted
Oct 16, 2023
Start date
Sep 22, 2024
Primary completion
Sep 22, 2024
Completion
Sep 22, 2024
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion